Роль иммунного микроокружения в развитии рака молочной железы

L. A. Sivak; A. N. Grabovyj; N. O. Verovkina; S. A. Lyalkin; N. M. Majdanevych; A. V. Askolskyy; M. Yu. Klimanov

doi:10.31640/LS-2017(1-2)12

L. A. Sivak National Cancer Institute
A. N. Grabovyj National Cancer Institute
N. O. Verovkina National Cancer Institute
S. A. Lyalkin National Cancer Institute
N. M. Majdanevych National Cancer Institute
A. V. Askolskyy National Cancer Institute
M. Yu. Klimanov National Cancer Institute

DOI: https://doi.org/10.31640/LS-2017(1-2)12

Keywords: breast cancer, tumor microenvirolement, chemotherapy, anti-HER2 therapy

Abstract

Traditionally, breast cancer has not been considered as a typical immunogenic tumor type. Nevertheless, it is well known that breast cancer is a heterogeneous mixture of different molecular subtypes and infiltration of tumor tissue by immunocompetent cells is associated with response to chemotherapy and survival in a certain molecular subtypes of breast cancer. Analysis of works of various research groups suggests that, immune markers, such as the presence of CD8 + lymphocytes, T regulatory cells in the tumor, as well as the ratio of CD8/CD4T should be used to stratify risk groups with prognostically unfavorable types of breast cancer as well as use as a factor in predicting the effectiveness of anti-HER2 therapy and chemotherapy for triple negative and HER2-overexpressing breast cancer subtypes.

Downloads

Download data is not yet available.

References

Заридзе Д. Г. Канцерогенез. – М.: Медицина, 2004. – 576 с.

Осинский С. П. Микроокружение опухолевых клеток и опухолевая прогрессия // Здоров’я України. – 2012. – № 12. – С. 34–35.

Ali1 H. R., Provenzano E., Dawson S.-J. еt al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients // Ann. Oncol. – 2014. – Vol. 25, N 8. – P. 1536–1543.

Andre F., Dieci M., Dubsky P. et al. Molecular Pathways: Involvement of Immune Pathways in theTherapeutic Response and Outcome in Breast Cancer // Clin. Cancer Res. – 2012. – Vol. 19, N 1. – P. 28–33.

Coulie P., van den Eynde B., van der Bruggen P. & Boon T. Tumor antigens recognized by T lymphocytes: at the core of cancer immunotherapy // Nature Reviews Oncology. – 2014. – Vol. 14, N 2. – P. 135–146.

Criscitiello Carmen. Tumor-Associated Antigens in Breast Cancer // Breast Care. – 2012. – N 7. – P. 262–266.

De Nardo D., Brennan D., Rexhepaj E. et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy // Cancer Discovery. – 2011. – Т 1. – Р. 54–67.

Denkert C., Darb-Esfahani S., Loibl S. et al. Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy // Semin Immunopathol. – 2011. – Vol. 33. – P. 341–351.

Denkert C., Loibl S., Noske A. et al. Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer // J. Clin. Oncol. – 2010. – Vol. 28, N 1. – P. 105–113.

Hanahan D., Weinberg R. A. The hallmarks of cancer // Cell. – 2000. – Vol. 100. – P. 57–70.

Hua Fang, Yves A. De Clerck. Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials // Cancer Res. – 2013. – Vol. 73, N 16. – P. 4965–4977.

Loi Sh., Sirtaine N., Piette F. et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 // J. Clin. Oncol. – 2013. – Vol. 31, N 7. – P. 860–867.

Loi1 S., Michiels S., Salgado R. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial // Ann. Oncol. – 2014. – Vol. 25, N 8. – P. 1544–1550.

Mahmoud S. M., Paish E. C., Powe D. G. et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer // Breast. Cancer Res. Treat. – 2011. – Vol.127. – P. 99–108.

Mahmoud Sh., Paish E., Powe D. G. et al. Tumor-Infiltrating CD8 Lymphocytes Predict Clinical Outcome in Breast Cancer // J. Clin. Oncol. – Vol. 29, N 15. – P. 1949–1955.

Ming-Ju Tsai, Wei-An Chang, Po-Lin Kuo. Tumor Microenvironment: A New Treatment Target for Cancer // ISRN Biochemistry. – 2014. – Article ID 351959.

Park S., Jiang Z., Mortenson E. D. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity // Cancer Cell. – 2010. – Vol. 18. – P. 160–170.

Ruffell B., Au A., Rugo H. S. et al. Leukocyte composition of human breast cancer // Proc. Natl. Acad. Sci. USA. – 2012. – Vol. 109. – P. 2796–2801.

Shiao S., Ganesan A., Rugo H., & Coussens L. Immune microenvironments in solid tumors: new targets for therapy // Genes & Development. – 2011. – Vol. 25. – P. 2559–2572.

Shigeoka M., Urakawa N., Nakamura T. et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma // Cancer Sci. – 2013. – Vol. 104, N 8. – P. 1112–1119.

Stagg John & Allard Bertrand. Immunotherapeutic approaches in triple negative breast cancer: latest research and clinical prospects // Ther Adv. Med. Oncol. – 2013. – Vol. 5, N 3. – P. 169–181.

Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion // Nat. Rev. Immunol. – 2006. – N 6. – P. 715–727.

Immune microenvironment in breast cancer

Abstract

Downloads

References